Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders

Drugs

Volumn 60, Issue 4, 2000, Pages 925-954

  Figgitt, D P ^a   McClellan, K J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CAFFEINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; FLUVOXAMINE; LITHIUM; PLACEBO; PROPRANOLOL; TACRINE; THEOPHYLLINE DERIVATIVE; WARFARIN;

ADULT; ANXIETY NEUROSIS; ASTHENIA; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEUROTOXICITY; OBSESSION; PANIC; PHARMACODYNAMICS; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; XEROSTOMIA;

EID: 0033762398     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060040-00006     Document Type: Review

References (211)

1. The public health impact of anxiety disorders: A WHO perspective
2. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
3. Health economics and cost implications of anxiety disorders and other mental disorders in the United States
4. New treatments for anxiety disorders: Clinical approaches for successful outcomes
5. Obsessive-compulsive disorder: Treatment options
6. Treatment of posttraumatic stress disorder
7. Treatment of obsessive-compulsive disorder
8. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety
9. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety
10. Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness
11. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
12. Fluvoxamine: An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders
13. Review of the animal pharmacology and pharmacokinetics of fluvoxamine
14. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor
15. Serotonin-selective antidepressants
16. Antidepressants and serotonin neurons of the raphe
17. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: An in vivo microdialysis study
18. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: Different effects of clomipramine and fluoxetine
19. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
20. Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
21. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder
22. 3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT(1A) binding site in the rat striatum
23. Evidence for a role of 5-HT(1C) receptors in the antiserotonergic properties of some antidepressant drugs
24. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor
25. Fluoxetine and two other serotonin reuptake inhibitors without affinity for neuronal receptors
26. Acute effects of atypical antidepressants on various receptors in the rat brain
27. Zimelidine: A review of its pharmacological properties and therapeutic efficacy in depressive illness
28. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro
29. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
30. The interaction of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) with sigma (σ) binding sites in human brain tissue
31. A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers
32. A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers
33. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers
34. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
35. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: One years experience
36. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients
37. Comparison of the (pro) convulsive properties of fluvoxamine and clomipramine with eight other antidepressants in an animal model
38. Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine
39. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers
40. The effect of anti-depressants on aversive periaqueductal gray stimulation in rats
41. Preclinical evidence on the psychotropic profile of fluvoxamine
42. Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents
43. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: A potential model for obsessive compulsive disorder
44. SSRIs and movement disorders: Is serotonin the culprit?
45. Movement disorders and abuse potential of the selective serotonin reuptake inhibitors
46. Overview of the pharmacokinetics of fluvoxamine
47. Clinical pharmacokinetics of fluvoxamine
48. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
49. Nonlinear pharmacokinetics of fluvoxamine and gender differences
50. Non-linear fluvoxamine disposition
51. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
52. Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design
53. Fluvoxamine maleate: Metabolism in man
54. Excretion of fluvoxamine in breast milk
55. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
56. Steady state pharmacokinetics of fluvoxamine in young and elderly volunteers
57. Kinetics of fluvoxamine in special populations
58. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose administration
59. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
60. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
61. Fluvoxamine inhibits the CYP2C 19-catalyzed bioactivation of chloroguanide
62. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
63. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
64. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
65. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
66. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole
67. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A
68. Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?
69. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro
70. A fluvoxamine-caffeine interaction study
71. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage
72. Elevated clozapine levels after fluvoxamine initiation
73. Elevated plasma levels of clozapine after concomitant use of fluvoxamine
74. Elevated levels of clozapine in serum after addition of fluvoxamine
75. Fluvoxamine-clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism
76. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
77. Fluvoxamine-clozapine dose-dependent interaction
78. Elevated clozapine plasma concentrations after fluvoxamine initiation
79. Fluvoxamine increases the clozapine serum levels significantly
80. Influence of fluvoxamine on tacrine metabolism in vitro: Potential implication for the hepatotoxicity in vivo
81. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans
82. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient
83. Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men
84. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients
85. Increased trimipramine plasma levels during fluvoxamine comedication
86. Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin
87. Toxic effects of theophylline caused by fluvoxamine
88. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline
89. Fluvoxamine-induced theophylline toxicity
90. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes
91. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers
92. Fluvoxamine-methadone interaction
93. Probable metabolic interaction between methadone and fluvoxamine in addict patients
94. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
95. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxaminelithium therapy
96. Chronic treatment with fluvoxamine, clovoxamine, and placebo: Interaction with digoxin and effects on sleep and alertness
97. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function
98. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study
99. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial
100. Efficacy of fluvoxamine in obsessive-compulsive disorder: Results of a multicentre, double blind, placebo-controlled trial
101. A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory
102. Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine
103. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
104. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison
105. A double-blind comparison of fluvoxamine and clomipramine in OCD
106. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison
107. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
108. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double-blind comparison with placebo
109. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine
110. Clinical usefulness of fluvoxamine maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double-blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110
111. Fluvoxamine treatment of obsessive-compulsive disorder
112. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome
113. Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)
114. Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study
115. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study
116. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year follow-up
117. Effect of fluvoxamine on panic disorder
118. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine
119. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline
120. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia
121. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder
122. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder
123. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks
124. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin
125. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia
126. Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone
127. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: A 2-year naturalistic follow-up
128. Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia
129. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
130. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine
131. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder
132. Fluvoxamine treatment for chronic PTSD: A pilot study
133. Fluvoxamine in civilians with posttraumatic stress disorder
134. Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors
135. The obsessive-compulsive spectrum disorders
136. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology
137. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa
138. Open trial of fluvoxamine in the treatment of bulimia nervosa
139. Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial
140. Short-term single-blind fluvoxamine treatment of pathological gambling
141. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling
142. Fluvoxamine treatment of body dysmorphic disorder
143. Efficacy and safety of fluvoxamine in body dysmorphic disorder
144. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia)
145. An open clinical trial of fluvoxamine treatment of psychogenic excoriation
146. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine
147. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder
148. Fluvoxamine treatment of trichotillomania
149. Fluvoxamine in the treatment of compulsive buying
150. Treatment of kleptomania with fluvoxamine
151. Buspirone augmentation of fluvoxamine in the treatment of kleptomania
152. Compulsive buying: A report of 20 cases
153. Compulsive buying: A review
154. Reliability and validity of a scale to measure change in persons with compulsive buying
155. Fluvoxamine. A review of its safety profile in world-wide studies
156. Prescription-event monitoring of 10401 patients treated with fluvoxamine
157. Psychopharmacology update
158. The serotonin syndrome and psychosis-like side-effects of fluvoxamine in clinical use - An estimation of incidence
159. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage
160. Serotonin syndrome and fluvoxamine: A case study
161. The behavioural toxicity of antidepressants: Effects on cognition and sexual function
162. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
163. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients
164. The SSRI discontinuation syndrome
165. SSRI discontinuation syndrome related to fluvoxamine
166. Is there a serotonergic withdrawal syndrome?
167. Serotonin reuptake inhibitor withdrawal
168. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal
169. Selective serotonin reuptake inhibitors and withdrawal symptoms: A review of the literature
170. SSRI safety in overdose
171. Acute fluvoxamine poisoning
172. Toleration and safety of sertraline: Experience worldwide
173. The side effect profile and safety of fluoxetine
174. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
175. SSRI treatment-emergent nausea
176. Effect of overweight and weight reduction with dietary therapy and/or fluvoxamine on liver function in obesity
177. Maintenance antidepressants and weight gain: A comparison of fluvoxamine and amitriptyline
178. Fluvoxamine versus amitriptyline in depressed hospital out-patients: A multicentre double-blind comparative trial
179. A risk-benefit assessment of pharmacological treatments for panic disorder
180. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis
181. Cardiac effects of antidepressant drugs: A comparison of the tricyclic antidepressants and fluvoxamine
182. The safety profile of fluvoxamine in elderly patients
183. The cardiotropic effect of antidepressants: A comparison with fluvoxamine
184. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients
185. Fluvoxamine: An antidepressant with low (or no) epileptogenic effect
186. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder
187. Fluvoxamine and convulsive syncope: Case report
188. Fluvoxamine
189. Antihistamine drug withdrawn by manufacturer
190. The safety of newly approved medicines: Do recent market removals mean there is a problem?
191. Anxiety disorders education campaign
192. Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis
193. Long term treatment of obsessive-compulsive disorder
194. SSRIs in the treatment of obsessive-compulsive disorder
195. Panic disorder: A treatment update
196. Current concepts in the treatment of panic disorder
197. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine
198. Comorbidity in social anxiety disorder: Impact on disease burden and management
199. Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard
200. Paroxetine: A review of its use in social anxiety disorder
201. Post-traumatic stress disorder: Pathophysiological aspects and pharmacological approaches to treatment
202. The role of serotonin in depression and anxiety
203. The SSRIs: Advantages, disadvantages and differences
204. Not so selective serotonin reuptake inhibitors
205. Comparing SSRIs: From chemistry to clinical choice
206. SSRI differentiation: Pharmacology and pharmacokinetics
207. Agents in development for anxiety disorders: Current status and future potential